Share this page!

NIAID News Profile picture
Twitter logo
12 Aug, 4 tweets, 2 min read
COVID-19 NEWS: Neutralizing antibody activity against all variants of #SARS-CoV-2, including Delta, lasted 6 months in people who got 2 doses of #COVID19 mRNA #vaccine. Findings online now @ScienceMagazine bit.ly/3fY1BEs
#NIAID, @EmoryMedicine researchers used multiple tests to measure different types of antibody response and whether they functioned against new virus variants.
Blood samples from 24 vaccinated people (8 each in 3 age groups) were drawn multiple times after vaccination. Most participants, including those over 71 years old, had detectable binding and functional antibodies at 6 months after 2nd dose.
The data called “encouraging” for use of mRNA vaccine in the face of viral variation.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with NIAID News

NIAID News Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @NIAIDNews

NIAID News Profile picture
10 Aug
COVID-19 NEWS: A new analysis of data (not yet peer-reviewed) from the Moderna #COVID19 vaccine Ph 3 trial adds evidence toward establishing a "correlate of protection"—a measurable marker of efficacy used to predict whether a vaccine will be protective bit.ly/CoP1273
The data indicate levels of neutralizing antibody responses strongly correlate with protection against symptomatic COVID-19. 4 kinds of tests showed that higher antibody levels correlated with higher estimated vaccine efficacy against symptomatic COVID-19.
Correlates of protection can help speed regulatory authorization & approval. Instead of large trials, samples from smaller groups of vaccinated people could be evaluated with a test indicating whether a vaccine is likely to have clinical benefit in that population.
Read 5 tweets
NIAID News Profile picture
19 Feb
NIAID investigators and collaborators at @ImmunoScape and @JHUcovidplasma recently published a study in @jclinicalinvest characterizing #Tcell responses in people who recover from #SARSCoV2 infection. jci.org/articles/view/…
T cells are a type of white blood cell part of the immune system & may allow for long-term protection against #SARSCoV2. Learning more about natural infection can help guide development of improved treatments and vaccines.
The researchers found that the majority of CD8+ T cells targeted internal and non-structural sites on viral proteins (epitopes), indicating possible targets for next-generation vaccines.
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @NIAIDNews has new unrolls!

Check out other threads from @NIAIDNews!

Read all threads by @NIAIDNews

:(